pharmaceuticals
18 articles
During Incyte's fourth quarter 2025 earnings call, executives reported stronger-than-expected commercial performance for 2025 and highlighted progress of their late-stage pipeline. CEO Bill noted that...
Novartis reported full-year 2025 results showing high single-digit sales growth and double-digit core operating income growth, hitting its 40% core margin target two years ahead of schedule. CEO Vas N...
Shares of Organon & Co., listed on NYSE as OGN, fell significantly in pre-market trading following an earnings report that did not meet expectations. The stock was previously closed at $7.69 and opene...
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $177.00 by Analysts at Royal Bank Of Canada
Royal Bank of Canada reduced its target price for Neurocrine Biosciences from $180 to $177 while maintaining an 'outperform' rating. The firm is among several analysts providing updates on the stock....
Investors from mainland China have boosted their investments in pharmaceutical and biotech firms listed on the Hong Kong stock exchange following a surge in licensing deals between Chinese drug makers...
During a Guggenheim fireside chat, Erasca executives discussed the company's approach to distinguishing itself in the RAS-focused drug development landscape. CFO David Chacko highlighted the competiti...
Citigroup has increased its target price for Neurocrine Biosciences stock (NASDAQ:NBIX) from $203.00 to $204.00, maintaining a 'buy' rating on the company....
In the third quarter, Caprock Group LLC purchased 141,096 shares of Teva Pharmaceutical Industries Ltd., valued at approximately $2,593,000, according to a recent SEC filing....
Equities research analysts at Truist Financial have upgraded their price target on Gilead Sciences (NASDAQ:GILD) from $145.00 to $152.00, maintaining a 'buy' rating....
On Tuesday, Fennec Pharmaceuticals (TSE:FRX) saw its stock price drop below the 50-day moving average of C$10.50, trading as low as C$10.32 and closing at C$10.53 with a modest volume of transactions....
Winslow Asset Management Inc. reduced its shareholding in Eli Lilly and Company (NYSE: LLY) by 1.9% in the third quarter. Following the sale of 609 shares, the firm now holds 31,616 shares of the phar...
New York Life Investment Management LLC reduced its holding of Vertex Pharmaceuticals Inc. shares in Q3 2023 by selling 1,468 shares. It now owns a total of 37,432 shares....
During the third quarter, AGF Management Ltd reduced its holdings in Vertex Pharmaceuticals Incorporated by selling 9,150 shares, resulting in a new holding of 7,735 shares. This represents a decrease...
Gilead Sciences (NASDAQ: GILD) has received a consensus recommendation of 'Moderate Buy' from analysts covering the company, according to Marketbeat.com. The analysis includes a hold rating from three...
Wolfe Research increased Gilead Sciences' stock price target from $155.00 to $170.00 and maintained an outperform rating, according to a recent research report....
Baader Bank Aktiengesellschaft has invested $885,000 in Madrigal Pharmaceuticals Inc. by purchasing 1,935 shares during the third quarter, as detailed in its latest SEC filing....
Machina Capital S.A.S has announced an acquisition of 14,848 shares in Gilead Sciences Inc., increasing its stake by approximately $1,648,000 in the third quarter, according to SEC documents....
Mission Wealth Management LP reduced its shareholding in Vertex Pharmaceuticals Incorporated by 30.5% during the third quarter through a sale of 1,742 shares, resulting in an ownership of 3,967 shares...